When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

Monoclonal antibodies like etesevimab have lost efficacy against Omicron subvariants, necessitating innovative solutions.

With memories of the devastating SARS-CoV-2 pandemic still fresh ... especially given its spike protein mutations that may help it evade immune responses. The detection of HKU5-CoV-2 in bats ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells ...

In this issue, C&EN takes a look at how the pandemic changed science and scientists and how science will continue to work to ...

New COVID Variant: In 2019, the world saw the emergence of the deadliest virus outbreak SARS-CoV-2, which caused COVID ... developed due to the continuous mutations happening in the spike protein ...

Several studies have suggested that COVID-19 may increase a person’s risk of developing cancer or promote metastasis of existing cancer.

Scientists found that it can bind to human ACE2 receptors, similar to SARS-CoV-2 (the virus behind COVID ... is still needed to track any potential mutations that could increase its infectiousness.

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...